AVA6000 Clinical Trials (2026): 1 Studies for Breast Cancer & Ovarian Carcinoma
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
1 AVA6000 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Breast Cancer & Ovarian Carcinoma) and 158 total planned enrollment. 1 AVA6000 clinical trial is actively recruiting at 3 U.S. sites across 3 states. Most recent activity: NCT04969835 (Aug 2026).
Where to Participate: All AVA6000 Trial Sites in the U.S. (3 sites across 3 states)
Every actively recruiting AVA6000trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT04969835 | Map |
| TX | University of Texas MD Anderson Cancer Center | Houston77030 | NCT04969835 | Map |
| WA | Fred Hutchinson Cancer Center | Seattle98109 | NCT04969835 | Map |
AVA6000 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P1 | 1 | 1 |
Recruiting AVA6000 clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT04969835 | A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours | P1 | Salivary Gland Tumor | 158 | Jul 2021 |
All AVA6000 trials (1)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT04969835 | A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours | P1 | recruiting | 158 | Avacta Life Sciences Ltd | Jul 2021 |
AVA6000 clinical trials: frequently asked questions
- How many AVA6000 clinical trials are there?
- 1 AVA6000 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
- Are AVA6000 clinical trials recruiting in 2026?
- Yes — 1 AVA6000 trial is actively recruiting in 2026, with 3 U.S. sites across 3 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is AVA6000 being studied for?
- AVA6000 is being studied for Breast Cancer, Ovarian Carcinoma, Salivary Gland Tumor, Soft Tissue Sarcoma, Urothelial Carcinoma. The trials are grouped by indication on this page.
- What phase is AVA6000 in?
- AVA6000 clinical trials span 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors AVA6000 clinical trials?
- The lead sponsor across the most AVA6000 trials is Avacta Life Sciences Ltd. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming AVA6000as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: